Login to Your Account



Earnings Roundup


Wednesday, February 8, 2012
• Amylin Pharmaceuticals Inc., of San Diego, reported 2011 non-GAAP operating income of $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010. Total revenues for the 12 months ending Dec. 31, 2011, were $650.7 million. Net product sales of $621 .6 million included $517.7 million for Byetta (exenatide) and $103.9 million for Symlin (pramlintide acetate). In comparison, Amylin reported net product sales of $651.1 million in 2010, including $559.3 million for Byetta and $91.8 million for Symlin. Non-GAAP operating income for the quarter ending Dec. 31 was $17.6 million, compared to non-GAAP operating income of $22.9 million for the same period in 2010.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription